The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

Abstract Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated with teclistamab at 13 U.S. centers throu...

Descrición completa

Detalles Bibliográficos

Principais autores:	Aimaz Afrough, Danai Dima, Beatrice Razzo, Utkarsh Goel, Aishwarya Sannareddy, Oren Pasvolsky, Mariola A. Vazquez-Martinez, Christopher J. Ferreri, Rahul Banerjee, Jack Khouri, James A. Davis, Mahmoud R. Gaballa, Alex Lieberman-Cribbin, Masooma S. Rana, Kelley Julian, Faiz Anwer, Leyla Shune, Shaun DeJarnette, Ariel F. Grajales-Cruz, Evguenia Ouchveridze, Gabriel De Avila, Sandra P. Susanibar-Adaniya, Andrew J. Portuguese, Daniel Schrum, Erin Eberwein, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Joseph P. McGuirk, Adriana Rossi, Megan M. Herr, Omar Castaneda, Frederick L. Locke, Shahzad Raza, Yi Lin, Shebli Atrash, Douglas W. Sborov, Peter M. Voorhees, Shambavi Richard, Alfred L. Garfall, Surbhi Sidana, Krina K. Patel, Doris K. Hansen, Andrew J. Cowan, Larry D. Anderson, Hans C. Lee
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Publishing Group 2025-11-01
Series:	Blood Cancer Journal
Acceso en liña:	https://doi.org/10.1038/s41408-025-01414-6
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!